MOD GRF(1-29) is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
ITI-333 is a drug which has a mixed mechanism of action, acting as an antagonist at the 5-HT2A, D1 and α1A receptors, and also as a partial agonist at the μ-opioid receptor. In animal studies it blocked the head-twitch response produced by DOI and also reduced responses to morphine, while also reducing the symptoms produced by naloxone-precipitated withdrawal in opioid habituated mice. It has been developed for potential uses in treatment of opioid withdrawal and opioid use disorder.
== Limitations == While chest radiographs are a relatively cheap and safe method of investigating diseases of the chest, there are a number of serious chest conditions that may be associated with a normal chest radiograph and other means of assessment may be necessary to make the diagnosis. For example, a patient with an acute myocardial infarction may have a completely normal chest radiograph.
== Interpretations == There are numerous interpretations of the doctrine of dependent origination across the different Buddhist traditions and within them as well. Various systematizations of the doctrine were developed by the Abhidharma traditions which arose after the death of the Buddha. Modern scholars have also interpreted the teaching in different ways. According to Ajahn Brahm, a fully correct understanding of dependent origination can only be known by awakened being or ariyas. Brahm notes that "this goes a long way to answering the question why there is so much difference of opinion on the meaning of dependent origination." Collett Cox writes that the majority of scholarly investigations of dependent origination adopt two main interpretations of dependent origination, they either see it as "a generalized and logical principle of abstract conditioning applicable to all phenomena" or they see it as a "descriptive model for the operation of action (karman) and the process of rebirth." According to Bhikkhu Analayo, there are two main interpretative models of the 12 nidanas in the later Buddhist exegetical literature, a model which sees the 12 links as working across three lives (the past life, the present life, the future life) and a model which analyzes how the 12 links are mental processes working in the present moment. Analayo argues that these are not mutually exclusive, but instead are complementary interpretations. Alex Wayman has argued that understanding the dependent origination formula requires understanding its two main interpretations.
=== Cancer === HSP expression plays a pivotal role in cancer identification. Recent discoveries have shown that high concentrations of eHSP can indicate the presence of contentious tumors. Additionally, HSPs have been shown to benefit oncologists in oral cancer diagnosis. Using techniques such as dot immunoassay and ELISA test researchers have been able to determine that HSP-specific phage antibodies could be beneficial in-vitro cancer diagnosis markers. HSPs have also been shown to interact with cancer adaptations such as drug resistance, tumor cell production and lifespan, and the up-regulation and down-regulation of oncomirs.
Sources: en.wikipedia.org
=== Move to Belgium === By 1929, several of the children were approaching the age to attend university and the family moved to a castle in the Belgian village of Steenokkerzeel near Brussels, where they were closer to several members of their family. Zita continued her political lobbying on behalf of the Habsburg family, even sounding out links with Mussolini's Italy. There was even a possibility of a Habsburg restoration under the Austrian Chancellors Engelbert Dollfuss and Kurt Schuschnigg, with Crown Prince Otto visiting Austria numerous times. These overtures were abruptly ended by the annexation of Austria by Nazi Germany in 1938. As exiles, the Habsburg family took the lead in resisting the Nazis in Austria, but this foundered because of opposition between monarchists and socialists.
Measurement of AFP is generally used in two clinical contexts. First, it is measured in pregnant women through the analysis of maternal blood or amniotic fluid as a screening test for certain developmental abnormalities, such as aneuploidy. Second, serum AFP level is elevated in people with certain tumors, and so it is used as a biomarker to follow these diseases. Some of these diseases are listed below:
They are not exposed on cell membranes, but are found in internal membranes, where they assist with the loading of antigenic peptides onto classic MHC class II molecules. The important nonclassical MHC class II molecule DM is only found from the evolutionary level of lungfish, although also in more primitive fishes both classical and nonclassical MHC class II are found.
By 2015, even at 90 years old, Mahathir remained sharp and combative. He repeatedly called for prime minister Najib Razak to resign over the 1Malaysia Development Berhad scandal (1MDB). On 30 August 2015, he and Siti Hasmah attended the Bersih 4 rally, a mass protest organised in response to the scandal. In 2016, Mahathir chaired the Malaysian Citizens' Declaration, which brought together several political figures and non-governmental organisations in calling for Najib's resignation. In this declaration, Mahathir listed 37 points. Later, the Citizens' Declaration reached one million signatures in May of the same year. In the 2016 Sungai Besar by-election, he supported Amanah and other Pakatan Harapan leaders, lending his influence to the opposition coalition. Mahathir left UMNO in 2016, and formed Parti Pribumi Bersatu Malaysia (BERSATU). The new party was officially registered on 9 September 2016, and Mahathir became its chairman. By 2017, he had officially joined the opposition coalition Pakatan Harapan. Negotiations then took place between different factions of the coalition for Mahathir to become the chairman and prime ministerial candidate. He assumed the position of chairman on 14 July 2017, despite reservations from supporters of Anwar Ibrahim, who could not contest in polls himself while imprisoned. In 2016, Mahathir had his police outriders withdrawn after his privileges were revoked due to his participation in anti-government events.
During World War II, he worked for the Admiralty Research Laboratory, from which many notable scientists emerged, including David Bates, Robert Boyd, Thomas Gaskell, George Deacon, John Gunn, Harrie Massey, and Nevill Mott; he worked on the design of magnetic and acoustic mines and was instrumental in designing a new mine that was effective against German minesweepers.
Sources: en.wikipedia.org
=== Valve Corporation v. Rothschild === In 2015, Display Technologies LLC, one of several IP-holding companies owned by Leigh Rothschild, sued Valve over patent infringement. While the suit was dismissed by January 2016, Valve shortly followed by acquiring licenses to twenty patents owned across Rothschild's firms. Around 2022, another Rothschild company, Patent Asset Management, began sending Valve demands to buy new licenses to two of the patents Valve already had licensed. Valve filed a lawsuit against the company in 2023 under Washington state's Patent Troll Protection and Consumer Protection Acts. In the months that followed, at least three lawsuits were filed in Texas by Rothschild's companies against Valve accusing Valve of additional patent infringement. Valve argued these suits were retaliatory to their Washington suit, and requested them to be dismissed. In February 2026, a jury found in Valve's favor on all counts.
In 1916, Popielski described histamine as a gastric secretagogue of hydrochloric acid. William Beaumont was an army surgeon who in 1825, was able to observe digestion as it took place in the stomach. This was made possible by experiments on a man with a stomach wound that did not fully heal leaving an opening into the stomach. The churning motion of the stomach was described among other findings. In the 19th century, it was accepted that chemical processes were involved in the process of digestion. Physiological research into secretion and the gastrointestinal tract was pursued with experiments undertaken by Claude Bernard, Rudolph Heidenhain and Ivan Pavlov. The rest of the 20th century was dominated by research into enzymes. The first to be discovered was secretin by Ernest Starling in 1902, with ensuing results from John Edkins in 1905 who first suggested gastrin with its structure being determined in 1964. Andre Latarjet and Lester Dragstedt found a role for acetylcholine in the digestive system. In 1972, H2 receptor agonists were described by J. Black, that block the action of histamine and decrease the production of hydrochloric acid. In 1980, proton pump inhibitors were described by Sachs. In 1983, the role of Helicobacter pylori in the formation of ulcers was described by Barry Marshall, and Robin Warren. Art historians have often noted that banqueters on iconographic records of ancient Mediterranean societies almost always appear to be lying down on their left sides. One possible explanation could lie in the anatomy of the stomach and in the digestive mechanism.
However, apart from the population of Na/K-ATPase in the plasma membrane, responsible for ion transport, there is another population in the caveolae which acts as digitalis receptor and stimulates the EGF receptor.
== Career == After gaining her doctorate, Ala-Kokko moved to Thomas Jefferson University in Philadelphia, United States, to carry out postdoctoral research in the group of Darwin Prockop. While there, Ala-Kokko focused her attention more directly on describing the structure, function and possible errors in genes that code for collagen proteins. She worked at Thomas Jefferson University as a research associate from 1987 to 1989, and as an instructor from 1989 to 1991. In 1990, Ala-Kokko was granted title of docent by the University of Oulu in the field of medical biochemistry. Her research work continued to be based in Philadelphia until 1997, when she was selected as a senior research fellow by the Academy of Finland. In the same year, Ala-Kokko also started at MCP Hahnemann University as an adjunct associate professor. In 2000, Ala-Kokko started work at the gene therapy centre of Tulane University in New Orleans. She worked there as an associate professor, and later became a full professor with tenure. In 2003 she was named professor of medical biochemistry and molecular biology at the University of Oulu. She left Tulane University in 2004. The company Connective Tissue Gene Tests was founded by Ala-Kokko in 2004 with her husband James Hyland. They offer over a thousand tests which function as molecular diagnostic tests of connective tissue disorders. As of 2018 her responsibility in the company is for research, development and technology. She is also responsible for overseeing all the tests that the company produces.
Dexamethasone is a fluorinated glucocorticoid medication used to treat rheumatic problems, a number of skin diseases, severe allergies, asthma, chronic obstructive pulmonary disease (COPD), croup, brain swelling, eye pain following eye surgery, superior vena cava syndrome (a complication of some forms of cancer), and along with antibiotics in tuberculosis. In adrenocortical insufficiency, it may be used in combination with a mineralocorticoid medication such as fludrocortisone. In preterm labor, it may be used to improve outcomes in the baby. It may be given by mouth, as an injection into a muscle, as an injection into a vein, as a topical cream or ointment for the skin or as a topical ophthalmic solution to the eye. The effects of dexamethasone are frequently seen within a day and last for about three days. The long-term use of dexamethasone may result in thrush, bone loss, cataracts, easy bruising, or muscle weakness. It is in pregnancy category C in the United States, meaning that it should only be used when the benefits are predicted to be greater than the risks. In Australia, the oral use is category A, meaning it has been frequently used in pregnancy and not been found to cause problems to the baby. It should not be taken when breastfeeding. Dexamethasone has anti-inflammatory and immunosuppressant effects. Dexamethasone was first synthesized in 1957 by Philip Showalter Hench and was approved for medical use in 1958. It is on the World Health Organization's List of Essential Medicines.
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.